Targets › CD4
6 programs from 6 companies in 12 trials: 6 Phase 1, 3 Phase 2, 2 Phase 3, 1 Phase 4; Infectious disease, Oncology, Metabolic and endocrine; next expected readout Jan 2027.
Integral membrane glycoprotein that plays an essential role in the immune response and serves multiple functions in responses against both external and internal offenses. In T-cells, functions primarily as a coreceptor for MHC class II molecule:peptide complex. (UniProt, P01730)
Open in Phaseline: the race on CD4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| GSK | Fostemsavir Envelope polyprotein GP160 inhibitor | INSTI, GP120, CD4 | Phase 3 | HIV Infections; HIV-1-infection; Human Immunodeficiency Virus (HIV); HIV Infections With Multi Drug Resistant Virus | Jan 2027 |
| TaiMed Biologics | TMB-365 HIV post-attachment inhibitor; monoclonal antibody that binds to CD4 receptor | CD4 | Phase 2 | HIV -1 Infection | May 2027 |
| PolTREG | ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs) Ex vivo expanded regulatory T cell therapy | CD4, CD25, IL2RA | Phase 2 | Presymptomatic Diabetes Type 1 (Stage 1) | Dec 2032 |
| Memorial Sloan Kettering Cancer Center | Antithymocyte globulin (ATG) Polyclonal antibody targeting T lymphocytes; immunosuppressant | CTLA4, CD2, CD3, CD4, CD8 | Phase 1 | Myeloid Diseases; Hematologic Malignancies | May 2027 |
| David Ho | Ibalizumab T-cell surface antigen CD4 inhibitor | CD4 | Phase 1 | HIV-1-infection | May 2027 |
| Huda Salman | CD4CAR CAR-T cell therapy targeting CD4 with anti-CD4 scFv derived from ibalizumab, with CD28 and | CD4 | Phase 1 | T-cell Lymphoma | Dec 2027 |
HIV Infections (3) HIV-1-infection (2) T-cell Lymphoma (1) Myeloid Diseases (1) Hematologic Malignancies (1) Human Immunodeficiency Virus (HIV) (1) HIV Infections With Multi Drug Resistant Virus (1) HIV -1 Infection (1) Presymptomatic Diabetes Type 1 (Stage 1) (1)
mixed (3), small molecule (2), protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.